PROCEPT BioRobotics (PRCT) is back in focus after its Q4 2025 revenue miss, softer 2026 outlook, and sharp share price ...
Analysts' ratings for PROCEPT BioRobotics (NASDAQ:PRCT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a concise overview of recent ratings by ...
Throughout the last three months, 7 analysts have evaluated PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of ...
Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased ...
Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, ...
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the Overlooked Small Cap Stocks to Buy Now. Wall Street is positive on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ahead of its fiscal Q4 2025 ...
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative ...
8d
PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...
Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results